SCHEMBL4870183

SCHEMBL4870183

CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(OC1CCCC1)S(=O)(=O)c1ccc2c(c1)OCCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
MLNR O43193 1/20 0.45
ABCB11 O95342 1/20 0.45
CTSD P07339 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP3A5 P20815 1/20 0.45
CNR1 P21554 1/20 0.45
TBXAS1 P24557 1/20 0.45
ADRA1A P35348 1/20 0.45
ALDH1A1 P00352 3/20 0.45
KLK5 Q9Y337 2/20 0.44
PSEN1 P49768 2/20 0.43
PSEN2 P49810 2/20 0.43
APH1B Q8WW43 2/20 0.43
NCSTN Q92542 2/20 0.43
APH1A Q96BI3 2/20 0.43
PSENEN Q9NZ42 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870176 1.00 LMNA (0.45) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4875283 0.96 KLK5 (0.43) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4875275 0.96 KLK5 (0.43) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4873631 0.89 ALDH1A1 (0.46) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4873623 0.89 ALDH1A1 (0.46) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4872813 0.88 MLNR (0.46) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4872807 0.88 MLNR (0.46) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL6617219 0.87 ABCB1 (0.57) LMNAMLNRABCB11CTSDCYP3A4
SCHEMBL4869050 0.87 KLK5 (0.46) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL4869053 0.87 KLK5 (0.46) KLK5PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US disclosed
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
EP-1086076-B1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2004-12-22 EP disclosed
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease HALE MICHAEL ROBIN (US) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP LMNA 3901/4885MLNR 4045/4885ABCB11 1899/4885
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP LMNA 3901/4885MLNR 4045/4885ABCB11 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.